Edesa Biotech to Join Panel Discussion at Government COVID-19 Event

Rhea-AI Summary

Edesa Biotech, Inc. (NASDAQ:EDSA) announced that CEO Dr. Par Nijhawan will join a virtual panel discussion titled Canadian Innovative COVID Solutions on January 26, 2021, at 2:20 PM ET. The event, organized by Clinical Trials Ontario, will focus on developing multiple countermeasures to the COVID-19 pandemic, including Edesa's EB05 drug candidate designed to treat Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. Edesa is advancing innovative treatments for inflammatory and immune-related diseases, with EB05 currently in late-stage clinical studies.

Positive

• Edesa's EB05 drug candidate is in late-stage clinical studies, targeting ARDS in COVID-19 patients.
• Participation in a government and industry panel highlights Edesa's commitment to addressing COVID-19.

Negative

• None.

TORONTO, ON / ACCESSWIRE / January 20, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event organized by Clinical Trials Ontario in collaboration with the Bureau du Québec à Toronto and the Canadian and International Innovation Partnerships Directorate. As part of a government and industry panel, Dr. Nijhawan is expected to discuss the importance of developing multiple countermeasures to the COVID-19 pandemic, including therapies, like Edesa's EB05 drug candidate, that target the overactive host immune response in COVID-19 patients.

The panel discussion, which is titled "Canadian Innovative COVID Solutions," is scheduled to take place on Thursday, January 26, 2021 at 2:20 PM Eastern Time. More information is available at the event website.

About Edesa Biotech, Inc.

Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that we are developing as a treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California. Sign up for news alerts.

Contact
Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
investors@edesabiotech.com

SOURCE: Edesa Biotech

View source version on accesswire.com:
https://www.accesswire.com/624892/Edesa-Biotech-to-Join-Panel-Discussion-at-Government-COVID-19-Event

FAQ

What is the purpose of Edesa Biotech's participation in the January 26 panel discussion?

Edesa Biotech's CEO will discuss developing therapies to combat COVID-19, emphasizing their EB05 drug candidate.

When is the virtual event involving Edesa Biotech scheduled?

The event is scheduled for January 26, 2021, at 2:20 PM Eastern Time.

What is Edesa Biotech focusing on in its drug development?

Edesa Biotech is focused on developing innovative treatments for inflammatory and immune-related diseases, including COVID-19.

What is the significance of the EB05 drug candidate?

EB05 is intended to treat Acute Respiratory Distress Syndrome (ARDS), a severe complication in COVID-19 patients.